FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

Abstract

BACKGROUND:

The aim of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL).

MATERIALS AND METHODS:

We retrospectively analyzed data from 59 relapsed or refractory FL patients treated with ibritumomab tiuxetan Y 90 in four different PET centers who had a PET scan carried out before and after RIT. Possible predictive factors of progression-free survival (PFS) were studied through univariate and multivariate analysis.

RESULTS:

The post-RIT PET documented 45.8% complete responders (CR), 25.4% partial responders (PR) and 28.8% nonresponders [stable disease + progressive disease], with an overall survival of 71.2% (range 59.5%-90.9%). With a median follow-up period of 23 months, the univariate analysis documented a statistically significant relation between disease extent before RIT and response to treatment with respect to PFS (P = 0.015), while all the other prognostic factors showed no significant correlation. When carrying out the multivariate analysis, post-RIT PET resulted as the lonely independent predictor of PFS (P < 0.00001).

CONCLUSIONS:

RIT is an effective therapy in FL patients, as confirmed in our study too. Disease extension before treatment and response to RIT, as assessed by FDG-PET, result as main predictors of PFS, with the post-RIT PET result being the only independent predictive factor.

• Authors: E Lopci, I Santi, E Derenzini, C Fonti, G Savelli, F Bertagna, M Bellò, B Botto, D Huglo, F Morschhauser, P Zinzani, S Fanti
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 21 Issue 9 Pg. 1877-1883 (Sep 2010) ISSN: 1569-8041 [Electronic] England
• PMID: 20147744 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antibodies, Monoclonal
• Radiopharmaceuticals
• Yttrium Radioisotopes
• Fluorodeoxyglucose F18
• ibritumomab tiuxetan

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (therapeutic use)
• Female
• Fluorodeoxyglucose F18
• Follow-Up Studies
• Humans
• Lymphoma, Follicular (diagnostic imaging, radiotherapy)
• Male
• Middle Aged
• Neoplasm Staging
• Positron-Emission Tomography
• Radiography
• Radioimmunotherapy
• Radiopharmaceuticals (therapeutic use)
• Retrospective Studies
• Survival Rate
• Treatment Outcome
• Yttrium Radioisotopes (therapeutic use)